CliffBio
small molecule

NAMENDA

MEMANTINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameNAMENDA
Active ingredientMEMANTINE HYDROCHLORIDE
Strength10MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2003
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NAMENDA patent cliff — loss of exclusivity — | CliffBio